Immune responses and transcription landscape of adults with the third dose of homologous and heterologous booster vaccines of COVID-19
- PMID: 39328415
- PMCID: PMC11424439
- DOI: 10.3389/fimmu.2024.1461419
Immune responses and transcription landscape of adults with the third dose of homologous and heterologous booster vaccines of COVID-19
Abstract
Background: Heterologous booster vaccines are more effective than homologous booster vaccines in combating the coronavirus disease 2019 (COVID-19) outbreak. However, our understanding of homologous and heterologous booster vaccines for COVID-19 remains limited.
Methods: We recruited 34 healthy participants from two cohorts who were primed with two-dose inactivated COVID-19 vaccine before, vaccinated with COVID-19 inactivated vaccine and adenovirus-vectored vaccine (intramuscular and aerosol inhalation of Ad5-nCoV) as a third booster dose. We assessed the immune responses of participants before and 14 days after vaccination, including levels of neutralizing antibodies, IgG, and cytokines, and quantified the transcriptional profile of peripheral blood mononuclear cells (PBMCs).
Results: The Ad5-nCoV group showed a significantly higher neutralizing antibody geometric mean titer (GMT) compared to the ICV group after 14 days of heterologous boosting. The intramuscular Ad5-nCoV group had a GMT of 191.8 (95% CI 129.0, 285.1) compared to 38.1 (95% CI 23.1, 62.8) in the ICV1 group (p<0.0001). The aerosolized Ad5-nCoV group had a GMT of 738.4 (95% CI 250.9-2173.0) compared to 244.0 (95% CI 135.0, 441.2) in the ICV2 group (p=0.0434). Participants in the aerosolized Ad5-nCoV group had median IFN-γ+ spot counts of 36.5 (IQR 15.3-58.8) per 106 PBMCs, whereas, both intramuscular Ad5-nCoV and CoronaVac immunization as the third dose showed lower responses. This suggests that a third dose of booster Ad5-nCoV vaccine (especially aerosolized inhalation) as a heterologous vaccine booster induces stronger humoral and cellular immune responses, which may be more potent against VOCs than the use of inactivated vaccine homologs. In transcriptomic analyses, both aerosolized inhalation/intramuscular injection of the Ad5-nCoV vaccine and inactivated vaccine induced a large number of differentially expressed genes that were significantly associated with several important innate immune pathways including inflammatory responses, regulation of the defense response, and regulation of cytokine production. In addition, we identified crucial molecular modules of protective immunity that are significantly correlated with vaccine type and neutralizing antibodies level.
Conclusion: This study demonstrated that inhalation/intramuscular injection of the Ad5-nCoV vaccine-mediated stronger humoral and cellular immune responses compared with the inactivated vaccine, and correlated significantly with innate immune function modules, supporting a heterologous booster immunization strategy.
Keywords: Ad5-nCoV; COVID-19; aerosol inhalation; immunity; intramuscular injection; transcriptome.
Copyright © 2024 Zheng, Li, Zheng, Jiang, Li, Yao, Li, Wang, Liu, Cao, Qi, Chen, Jin, Zhu, Li and Chen.
Conflict of interest statement
Author XZ, XL, and FW were employed by CanSino Biologics Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures




Similar articles
-
Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.Lancet Infect Dis. 2021 Dec;21(12):1654-1664. doi: 10.1016/S1473-3099(21)00396-0. Epub 2021 Jul 26. Lancet Infect Dis. 2021. PMID: 34324836 Free PMC article. Clinical Trial.
-
Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trial.Lancet Respir Med. 2023 Jul;11(7):613-623. doi: 10.1016/S2213-2600(23)00049-8. Epub 2023 Mar 7. Lancet Respir Med. 2023. PMID: 36898400 Free PMC article. Clinical Trial.
-
Antibody dynamics for heterologous boosters with aerosolized Ad5-nCoV following inactivated COVID-19 vaccines.Hum Vaccin Immunother. 2024 Dec 31;20(1):2423466. doi: 10.1080/21645515.2024.2423466. Epub 2024 Nov 13. Hum Vaccin Immunother. 2024. PMID: 39535117 Free PMC article.
-
Safety, immunogenicity, and protective effective of inhaled COVID-19 vaccines: A systematic review and meta-analysis.J Med Virol. 2024 Apr;96(4):e29625. doi: 10.1002/jmv.29625. J Med Virol. 2024. PMID: 38650361
-
A China-developed adenovirus vector-based COVID-19 vaccine: review of the development and application of Ad5-nCov.Expert Rev Vaccines. 2023 Jan-Dec;22(1):704-713. doi: 10.1080/14760584.2023.2242528. Expert Rev Vaccines. 2023. PMID: 37501516 Review.
References
-
- WHO . WHO coronavirus (COVID-19) dashboard (2023). Available at: https://covid19.who.int. (Accessed May 2, 2024)
-
- Tang R, Zheng H, Wang B-S, Gou J-B, Guo X-L, Chen X-Q, et al. . Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trial. Lancet Respir Med. (2023) 11:613–23. doi: 10.1016/S2213-2600(23)00049-8 - DOI - PMC - PubMed
-
- Li J-X, Wu S-P, Guo X-L, Tang R, Huang B-Y, Chen X-Q, et al. . Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial. Lancet Respir Med. (2022) 10:739–48. doi: 10.1016/S2213-2600(22)00087-X - DOI - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical